Myeloproliferative Neoplasms

Critical Concepts and Management


ISBN: 978-3-642-24988-4 (Print) 978-3-642-24989-1 (Online)

Table of contents (18 chapters)

  1. Front Matter

    Pages i-viii

  2. Biology

    1. Front Matter

      Pages 1-1

    2. Chapter

      Pages 3-10

      Update on the Biology of Myeloproliferative Neoplasms

    3. Chapter

      Pages 11-16

      Do We Need Biological Studies for Patient Management?

  3. General issues in the management of MPNs

    1. Front Matter

      Pages 17-17

    2. Chapter

      Pages 19-35

      Critical Issues About the Diagnosis of MPNs: Bone Marrow Histopathology

    3. Chapter

      Pages 37-45

      Critical Issues About the Diagnosis of Myeloproliferative Neoplasms: World Health Organization Classification

    4. Chapter

      Pages 47-55

      Patient’s Information and Examinations Needed Before Planning Therapy in the Myeloproliferative Neoplasms

    5. Chapter

      Pages 57-67

      Mechanisms of Thrombogenesis

  4. Specific issues of Treatment in PV and ET

    1. Front Matter

      Pages 69-69

    2. Chapter

      Pages 71-84

      Risk Classification

    3. Chapter

      Pages 85-92

      Goal of Therapy and Monitoring the Response in Polycythemia Vera and Essential Thrombocythemia

    4. Chapter

      Pages 93-104

      First-Line Therapy and Special Issues Management in Polycythemia Vera and Essential Thrombocythemia

    5. Chapter

      Pages 105-118

      Primary and Secondary Antithrombotic Prophylaxis

    6. Chapter

      Pages 119-129

      Polycythemia Vera and Essential Thrombocythemia: When to Change Therapy – Second-Line Options

    7. Chapter

      Pages 131-145

      Blastic Transformation of BCR-ABL-Negative Myeloproliferative Neoplasms

  5. Treatment of PMF

    1. Front Matter

      Pages 147-147

    2. Chapter

      Pages 149-161

      Current Clinical Needs

    3. Chapter

      Pages 163-175

      Risk Stratification in PMF

    4. Chapter

      Pages 177-186

      Nontransplant Treatment Options for Myelofibrosis: How to Treat Anemia, Splenomegaly, Constitutional Symptoms, and Extramedullary Disease

    5. Chapter

      Pages 187-199

      Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis

  6. Research issues and perspectives

    1. Front Matter

      Pages 201-201

    2. Chapter

      Pages 203-214

      A Critical Review of the Role and Limitations of JAK Inhibitors in Myelofibrosis Therapy

    3. Chapter

      Pages 215-232

      Ongoing Clinical Trials in Myeloproliferative Neoplasms

  7. Back Matter

    Pages 233-240